213 related articles for article (PubMed ID: 35173744)
1. Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
Díaz-García E; García-Tovar S; Alfaro E; Zamarrón E; Mangas A; Galera R; Ruíz-Hernández JJ; Solé-Violán J; Rodríguez-Gallego C; Van-Den-Rym A; Pérez-de-Diego R; Nanwani-Nanwani K; López-Collazo E; García-Rio F; Cubillos-Zapata C
Front Immunol; 2022; 13():847894. PubMed ID: 35173744
[TBL] [Abstract][Full Text] [Related]
2. Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.
Jalkanen J; Yegutkin GG; Hollmén M; Aalto K; Kiviniemi T; Salomaa V; Jalkanen S; Hakovirta H
Circ Res; 2015 Mar; 116(7):1206-15. PubMed ID: 25645301
[TBL] [Abstract][Full Text] [Related]
3. Purinergic dysregulation in pulmonary hypertension.
Visovatti SH; Hyman MC; Goonewardena SN; Anyanwu AC; Kanthi Y; Robichaud P; Wang J; Petrovic-Djergovic D; Rattan R; Burant CF; Pinsky DJ
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H286-98. PubMed ID: 27208163
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and Mortality.
Gambichler T; Rüth J; Goesmann S; Höxtermann S; Skrygan M; Susok L; Becker JC; Overheu O; Schmidt W; Reinacher-Schick A
Viruses; 2024 May; 16(5):. PubMed ID: 38793691
[TBL] [Abstract][Full Text] [Related]
5. Role of extracellular ATP metabolism in regulation of platelet reactivity.
Birk AV; Broekman MJ; Gladek EM; Robertson HD; Drosopoulos JH; Marcus AJ; Szeto HH
J Lab Clin Med; 2002 Sep; 140(3):166-75. PubMed ID: 12271274
[TBL] [Abstract][Full Text] [Related]
6. High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.
da Silva GB; Manica D; da Silva AP; Kosvoski GC; Hanauer M; Assmann CE; Simões JLB; Pillat MM; de Lara JD; Marafon F; Bertollo AG; Mingoti MED; Gavioli J; Réus GZ; de Oliveira GG; Ignácio ZM; Bagatini MD
J Mol Med (Berl); 2022 Apr; 100(4):645-663. PubMed ID: 35249135
[TBL] [Abstract][Full Text] [Related]
7. Alterations in CD39/CD73 axis of T cells associated with COVID-19 severity.
Dorneles GP; Teixeira PC; da Silva IM; Schipper LL; Santana Filho PC; Rodrigues Junior LC; Bonorino C; Peres A; Fonseca SG; Monteiro MC; Boeck CR; Eller S; Oliveira TF; Wendland EM; Romão PRT
J Cell Physiol; 2022 Aug; 237(8):3394-3407. PubMed ID: 35754396
[TBL] [Abstract][Full Text] [Related]
8. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients.
Pietrobon AJ; Andrejew R; Custódio RWA; Oliveira LM; Scholl JN; Teixeira FME; de Brito CA; Glaser T; Kazmierski J; Goffinet C; Turdo AC; Yendo T; Aoki V; Figueiró F; Battastini AM; Ulrich H; Benard G; Duarte AJDS; Sato MN
Front Immunol; 2022; 13():1012027. PubMed ID: 36248842
[TBL] [Abstract][Full Text] [Related]
10. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
11. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
12. Thrombo-Inflammation: A Focus on NTPDase1/CD39.
Morello S; Caiazzo E; Turiello R; Cicala C
Cells; 2021 Aug; 10(9):. PubMed ID: 34571872
[TBL] [Abstract][Full Text] [Related]
13. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
14. Vascular Damage, Thromboinflammation, Plasmablast Activation, T-Cell Dysregulation and Pathological Histiocytic Response in Pulmonary Draining Lymph Nodes of COVID-19.
Haslbauer JD; Zinner C; Stalder AK; Schneeberger J; Menter T; Bassetti S; Mertz KD; Went P; Matter MS; Tzankov A
Front Immunol; 2021; 12():763098. PubMed ID: 34966385
[TBL] [Abstract][Full Text] [Related]
15. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
16. Characterization of soluble CD39 (SolCD39/NTPDase1) from PiggyBac nonviral system as a tool to control the nucleotides level.
Beckenkamp LR; Iser IC; Onzi GR; Fontoura DMSD; Bertoni APS; Sévigny J; Lenz G; Wink MR
Biochem J; 2019 Jun; 476(11):1637-1651. PubMed ID: 31085558
[TBL] [Abstract][Full Text] [Related]
17. Altered E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle cell anemia patients.
Castilhos LG; Doleski PH; Adefegha SA; Becker LV; Ruchel JB; Leal DB
Biomed Pharmacother; 2016 Apr; 79():241-6. PubMed ID: 27044834
[TBL] [Abstract][Full Text] [Related]
18. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.
Sriram K; Insel PA
Physiol Rev; 2021 Apr; 101(2):545-567. PubMed ID: 33124941
[TBL] [Abstract][Full Text] [Related]
19. NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD.
Lazar Z; Müllner N; Lucattelli M; Ayata CK; Cicko S; Yegutkin GG; De Cunto G; Müller T; Meyer A; Hossfeld M; Sorichter S; Horvath I; Virchow CJ; Robson SC; Lungarella G; Idzko M
Eur Respir J; 2016 Jan; 47(1):254-63. PubMed ID: 26541524
[TBL] [Abstract][Full Text] [Related]
20. Purinergic signaling in infectious diseases of the central nervous system.
Alves VS; Leite-Aguiar R; Silva JPD; Coutinho-Silva R; Savio LEB
Brain Behav Immun; 2020 Oct; 89():480-490. PubMed ID: 32717399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
